# A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

> **NCT07309055** · PHASE3 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 201 (estimated)

## Conditions studied

- Adolescents With Moderate-to-severe Atopic Dermatitis

## Interventions

- **DRUG:** SHR-1819 Injection
- **DRUG:** SHR-1819 Injection Placebo

## Key facts

- **NCT ID:** NCT07309055
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-21
- **Primary completion:** 2027-11
- **Final completion:** 2027-12
- **Target enrollment:** 201 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07309055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07309055, "A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07309055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*